Free Growth Stock Membership Sign Up

cropped-stockreversals-jpg-logo-copy-640x310.jpg

FREE: Subscribe To StockReversals Business Disruptor Research reports and stock ideas membership.

Our latest Email report on May 5th was to consider buying JUNO at $44.  Just 4 weeks later the stock hit all time highs of $68 for a 54% gain.  Here is what we sent out.

 Join Free Today and be in line for our Weekend Reports and next Business Disruptor Research Report E-mailed to you with password and link to SR members only.

You can check into our Stock Reversals Premium Trading membership here (stockreversalspremium.com)

Over 8,500 Traders follow us in real time on Stocktwits.com, find out why below…

free sign up

sr stocktwits xon

Your advice is amazing… I really just need to follow your every move. Thanks for providing such great advice and guidance.- Andrew B. SRP Member 4/1/15

I’m a very enthusiastic recent member (since late Dec. 2014).  I have never had a run like this.  Really appreciate the great long calls and the timely swings.  Keep up the great work. Blessings… Daniel H.  SRP Member 3/4/15
sr blue

 Why opt in for our reports?

Our track record is off the charts good at finding massive growth stock gainers before the crowds: In addition, our SRP Premium trading service has beat the SP 500 over 5 to 1!

Stockreversals.com Free Research Report Samples:

chrs twits2

54% Gain!

JUNO–  We e-mailed out a bottom buy alert on 5/5/15 and just 4 weeks later the stock had soared 54% climbing from $44 at time of our Email report to $68, all time highs!

175% Gain!

TASER–  Written up in 2013 at $12 per share, we identified the new Body cameras for Police as a disrupting product cycle ahead for Taser.  The stock has gone from $12 to $33 in 17 months for a 175% gain

130% Gain!

CHRS– Written up in November 2014 after the IPO at $14 per share. We identified “Biosimilars” as the next big thing in Biotech drug development.  The stock ran from 14 to 32 in the few months that followed our report for a 130% gain

600% Gain!

sr blue twits

BLUE- Recommended Bluebird Bio in late May 2014 after the Biotech sector had been hammered. We said they were curing forms of Blood Cancer.  The stock has since soared from $23 to $134 in 12 months for a 600% gain.

100% Gain!

DATA–  We called them “The Next Microsoft” in the fall of 2013 at $55 per share.  The stock has since doubled as they transform data analysis from the old spreadsheet model to a graphical interface model and customers have soared.

These are only a few of about 50 reports we have written up of which 90% have risen 25% or more since our 9/1/13 inception.  Join us today before our next report is sent out (usually 1-2 per month).

Others: ZLTQ 18 to 33 80% ; QURE 18 to 34 in 2 months for 80%; TRVN 5.75 to 8.25 in 3 weeks for 35%;

free sign up

 

We are also “Seeking Alpha Certified” @ Seekingalpha.com

seeking alpha certified

 

 

  • We E-mail occasional reports on growth stocks in the right sectors
  • We write full reports on the up and coming small to mid cap names
  • We send you updates on prior reports
  • We send you a Weekend Report most weekends with 10-12 fresh ideas, market forecast updates, charts and more.

Our track record in spotting growth stocks before the crowd is unmatched. We have over 7,500 followers on Stocktwits and growing.  Join us today and see some of our work at no obligation. If you like it, consider joining our Premium service down the road.

You also become eligible to join our StockReversals Premium service, which is limited in number of subscribers and has beat the market 5 to 1 since 9/2013 inception.

Disclaimer:
This material should not be considered investment advice. StockReversalsPremium.com and any of our affiliates are not a registered investment advisor. Under no circumstances should any content from this website, articles, videos, seminars or emails from Stockreversals.com or Stockreversalspremium.com or its affiliates be used or interpreted as a recommendation to buy or sell any type of security or commodity contract. This material is not a solicitation for a trading approach to financial markets. Any investment decisions must in all cases be made by the reader or by his or her registered investment advisor. This information is for educational purposes only. 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s